Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Design Therapeutics Inc

Current price
4.55 USD -0.03 USD (-0.66%)
Last closed 4.48 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 246 318 208 USD
Yield for 12 month -34.81 %
21.11.2021 - 28.11.2021

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California. Address: 6005 Hidden Valley Road, Carlsbad, CA, United States, 92011

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

6.67 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

+838 000 USD

Current Year

-537 000 USD

Last Year

-466 000 USD

Current Quarter

-143 000 USD

Last Quarter

+700 000 USD

Key Figures DSGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -70 388 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -14.69 %
PEG Ratio
Return On Equity TTM -20.15 %
Wall Street Target Price 6.67 USD
Revenue TTM 33 000 USD
Book Value 4.77 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM -48 613 000 USD
Earnings per share -1.04 USD
Diluted Eps TTM -1.04 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics DSGN

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History DSGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation DSGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 11004.3527
Price Sales TTM 22642.0122
Enterprise Value EBITDA -0.8361
Price Book MRQ 0.9138

Financials DSGN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators DSGN

For 52 weeks

1.94 USD 8.31 USD
50 Day MA 3.91 USD
Shares Short Prior Month 2 867 329
200 Day MA 2.97 USD
Short Ratio 17.71
Shares Short 2 953 794
Short Percent 11.61 %

Dynamics of changes in the value of assets



1.28 EUR GENESIS MIN +0.05 (+4.07%)
Detailed analytics


0.21 EUR Gaussin SA 0 (0%)
Detailed analytics


0.57 HKD Langham Hospitality Invest Ltd 0 (0%)
Detailed analytics


0.35 USD Obrascón Huarte Lain S.A 0 (0%)
Detailed analytics


1 907.00 JPY Nichiban Co Ltd +0.02 (+0.16%)
Detailed analytics